LUMIFY (brimonidine tartrate) · BAUSCH AND LOMB INC
LUMIFY is FDA-approved to treat 2 conditions (same as BRIMONIDINE TARTRATE).
Details
- Status
- Over-the-counter
- First Approved
- 2017-12-22
- Patent Cliff
- 2030
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION/DROPS
LUMIFY Approval History
What LUMIFY Treats
2 indicationsLUMIFY is approved for 2 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.
Same approved indications as BRIMONIDINE TARTRATE (same active ingredient).
BAUSCH AND LOMB INC's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Clinical Trial Registry
12 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05270863 results posted | VT-002 | Ph 3 | completed | Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia |
| NCT03785340 results posted | OCU-310-301 | Ph 3 | completed | Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED) |
| NCT03591874 oGVHD results posted | OCU-300-301 | Ph 3 | terminated | Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease |
| NCT03760185 results posted | 18-1713 | Ph 2 | completed | Pupil Dilation for Treatment of IFIS |
| NCT03323164 results posted | 17-636E | Ph 4 | completed | Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study |
| NCT01959230 results posted | 861 | Ph 3 | completed | Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness |
| NCT01959243 results posted | 862 | Ph 3 | completed | Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants |
| NCT03966560 | KAEK-2014/04-74 | Ph 4 | completed | Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma |
| NCT03173365 BRIMOCAN | BRIMOCAN | Ph 2 | terminated | The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients |
| NCT02039765 | 863/13-100-0007 | Ph 1 | completed | Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%. |
| NCT02856919 BR14004 | BR.14.004 | Ph 4 | completed | A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema. |
| NCT02568111 BRITE | NLD-PEG-14-10784 2015-002159-89 | Ph 4 | withdrawn | Brimonidine Tartrate for the Treatment of Injection Related Erythema |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LUMIFY FDA Label Details
Indications & Usage
FDA Label (PDF)LUMIFY is FDA-approved to treat 2 conditions — same approved indications as BRIMONIDINE TARTRATE.
LUMIFY Patents & Exclusivity
Patents (4 active)
Pro Intelligence Preview
Deep insights for LUMIFY
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2030
- • 4 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.